1
|
Raia-Barjat T, Edebiri O, Ni Ainle F. Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy. Front Cardiovasc Med 2022; 9:856923. [PMID: 35345482 PMCID: PMC8957069 DOI: 10.3389/fcvm.2022.856923] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 02/11/2022] [Indexed: 12/23/2022] Open
Abstract
Preeclampsia (PET) is a multisystem inflammatory disorder that represents a leading cause of feto-maternal morbidity and mortality, complicating 2–5% of all pregnancies. PET incurs an increased risk of venous thromboembolism, which is one of the leading causes of death in pregnancy and in the postpartum period. This prothrombotic phenotype is attributable to the maternal phase of PET, which is characterized by a systemic inflammatory response and coagulation activation. Research continues to be undertaken in terms of preventative measures, however, currently revolves around pharmacological low dose aspirin initiated in the first trimester of pregnancy for those with risk factors. Treatment involves antenatal corticosteroids for fetal lung development in preterm birth, parenteral magnesium sulfate for fetal neuroprotection and maternal seizure prophylaxis, and timely birth of the fetus and placenta being the only definitive treatment of PET. Patients with a venous thromboembolism (VTE) risk deemed to be >1–3% are treated with pharmacological thromboprophylaxis in the form of low molecular weight heparin. Completing each woman’s VTE risk assessment is crucial, particularly in the setting of PET, as there is also a proven associated competing hemorrhagic risk.
Collapse
Affiliation(s)
- Tiphaine Raia-Barjat
- Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France
- INSERM U1059, SAINBIOSE, Université Jean Monnet, Saint-Étienne, France
- *Correspondence: Tiphaine Raia-Barjat,
| | - Osasere Edebiri
- Department of Haematology, Mater Misericordiae University Hospital, Rotunda Hospital, Dublin, Ireland
| | - Fionnuala Ni Ainle
- Department of Haematology, Mater Misericordiae University Hospital, Rotunda Hospital, Dublin, Ireland
- UCD School of Medicine, University College Dublin, Dublin, Ireland
| |
Collapse
|
2
|
Guerby P, Tasta O, Swiader A, Pont F, Bujold E, Parant O, Vayssiere C, Salvayre R, Negre-Salvayre A. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol 2021; 40:101861. [PMID: 33548859 PMCID: PMC7873691 DOI: 10.1016/j.redox.2021.101861] [Citation(s) in RCA: 96] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 12/30/2020] [Accepted: 01/05/2021] [Indexed: 12/25/2022] Open
Abstract
Preeclampsia (PE) is a multifactorial pregnancy disease, characterized by new-onset gestational hypertension with (or without) proteinuria or end-organ failure, exclusively observed in humans. It is a leading cause of maternal morbidity affecting 3–7% of pregnant women worldwide. PE pathophysiology could result from abnormal placentation due to a defective trophoblastic invasion and an impaired remodeling of uterine spiral arteries, leading to a poor adaptation of utero-placental circulation. This would be associated with hypoxia/reoxygenation phenomena, oxygen gradient fluctuations, altered antioxidant capacity, oxidative stress, and reduced nitric oxide (NO) bioavailability. This results in part from the reaction of NO with the radical anion superoxide (O2•−), which produces peroxynitrite ONOO-, a powerful pro-oxidant and inflammatory agent. Another mechanism is the progressive inhibition of the placental endothelial nitric oxide synthase (eNOS) by oxidative stress, which results in eNOS uncoupling via several events such as a depletion of the eNOS substrate L-arginine due to increased arginase activity, an oxidation of the eNOS cofactor tetrahydrobiopterin (BH4), or eNOS post-translational modifications (for instance by S-glutathionylation). The uncoupling of eNOS triggers a switch of its activity from a NO-producing enzyme to a NADPH oxidase-like system generating O2•−, thereby potentiating ROS production and oxidative stress. Moreover, in PE placentas, eNOS could be post-translationally modified by lipid peroxidation-derived aldehydes such as 4-oxononenal (ONE) a highly bioreactive agent, able to inhibit eNOS activity and NO production. This review summarizes the dysfunction of placental eNOS evoked by oxidative stress and lipid peroxidation products, and the potential consequences on PE pathogenesis. Physiological ROS production is enhanced during pregnancy. eNOS is one of the main target of oxidative stress in PE placenta. eNOS is S-glutathionylated in PE placentas. eNOS is modified by lipid oxidation products in PE placentas.
Collapse
Affiliation(s)
- Paul Guerby
- Inserm U1048, Université de Toulouse, France; Gynecology and Obstetrics Department, Paule-de-Viguier Hospital, Toulouse University Hospital, France; Pôle Technologique du CRCT, Toulouse, France
| | - Oriane Tasta
- Inserm U1048, Université de Toulouse, France; Gynecology and Obstetrics Department, Paule-de-Viguier Hospital, Toulouse University Hospital, France
| | | | | | - Emmanuel Bujold
- Reproduction, Mother and Child Health Unit, CHU de Québec - Université Laval Research Centre, Université Laval, Québec, Canada
| | - Olivier Parant
- Gynecology and Obstetrics Department, Paule-de-Viguier Hospital, Toulouse University Hospital, France
| | - Christophe Vayssiere
- Gynecology and Obstetrics Department, Paule-de-Viguier Hospital, Toulouse University Hospital, France
| | | | | |
Collapse
|
3
|
Bénin A, Blanc M, Chollat C, Jarreau PH, Goffinet F, Tsatsaris V, Delorme P. The cause of birth is associated with neonatal prognosis in late preterm singletons. J Gynecol Obstet Hum Reprod 2020; 49:101920. [PMID: 32971309 DOI: 10.1016/j.jogoh.2020.101920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 09/17/2020] [Accepted: 09/18/2020] [Indexed: 11/20/2022]
Abstract
INTRODUCTION Recent studies have shown that the cause of very preterm births may be related to neonatal morbidity and mortality. Even though these risks are lower among late preterm births, this group accounts for the vast majority of all preterm births. The objective of this study was to evaluate the relation of neonatal morbidity and mortality to the cause of late preterm birth. MATERIALS AND METHODS This retrospective observational cohort study included all women who gave birth to liveborn singletons from 34 to 36 weeks+6 days of gestation in a French level III maternity hospital in the 5-year period 2013-2017. The causes of preterm delivery were divided into 6 mutually exclusive groups. The main outcome was a composite neonatal morbidity criterion, defined by at least one among the following criteria: neonatal respiratory distress, neurological complications, neonatal sepsis, severe necrotizing enterocolitis, and neonatal hypoglycemia. We analyzed the association between cause of preterm delivery and neonatal morbidity after adjustment for gestational age and antenatal corticosteroid therapy. The reference group was preterm labor, defined by spontaneous preterm labor with intact membranes. RESULTS During the study period, there were a total of 27 110 births, including 1114 singleton births at 34 to 36 weeks of gestation + 6 days (4.1%). Among the 968 late preterm births included, the risk of neonatal morbidity in the group with preterm premature rupture of membranes (PPROM) was similar to that in the preterm labor (reference) group: adjusted odds ratio (aOR) 1.2 (95% CI, 0.8-1.8). All the other causes of late preterm birth were associated with a higher risk of neonatal morbidity than the reference group: aOR 2.0 [95% CI, 1.1-3.5] for hypertensive disorders without suspected fetal growth restriction (FGR) (9.1% of cases), aOR 2.4 [95% CI, 1.4-4.2] for hypertensive disorders with suspected FGR (8.9%), aOR 4.2 [95% CI, 2.2-8.0] for suspected FGR without hypertensive disorders (5.8%), and aOR 4.4 [95% CI, 2.2-8.8] for vaginal bleeding related to abnormal placental insertion (4.7%). CONCLUSION Among infants born from 34 to 36 weeks + 6 days of gestation, PPROM and preterm labor had similar risks of neonatal morbidity, while the other causes were associated with a risk of neonatal morbidity at least twice that with preterm labor.
Collapse
Affiliation(s)
- Amélie Bénin
- Maternité Port-Royal, AP-HP, APHP. Centre-Université de Paris, FHU PREMA, Paris, France(1).
| | - Matthieu Blanc
- Maternité Port-Royal, Service de réanimation néonatale, AP-HP, APHP. Centre-Université de Paris, Paris, France
| | - Clément Chollat
- Maternité Port-Royal, Service de réanimation néonatale, AP-HP, APHP. Centre-Université de Paris, Paris, France; INSERM U1245, Genetics and Pathophysiology of Neurodevelopmental Disorders, Team 4 Neovasc, Institute of Research and Innovation in Biomedicine, Normandy University, Rouen, France
| | - Pierre-Henri Jarreau
- Maternité Port-Royal, Service de réanimation néonatale, AP-HP, APHP. Centre-Université de Paris, Paris, France
| | - François Goffinet
- Maternité Port-Royal, AP-HP, APHP. Centre-Université de Paris, FHU PREMA, Paris, France(1); Université de Paris, INSERM U1153, Equipe de recherche en Epidémiologie Obstétricale, Périnatale et Pédiatrique (EPOPé), Centre de Recherche Epidémiologie et Biostatistique Sorbonne Paris Cité (CRESS), Paris, France
| | - Vassilis Tsatsaris
- Maternité Port-Royal, AP-HP, APHP. Centre-Université de Paris, FHU PREMA, Paris, France(1)
| | - Pierre Delorme
- Université de Paris, INSERM U1153, Equipe de recherche en Epidémiologie Obstétricale, Périnatale et Pédiatrique (EPOPé), Centre de Recherche Epidémiologie et Biostatistique Sorbonne Paris Cité (CRESS), Paris, France; Sorbonne Université, AP-HP, Department of Gynaecology and Obstetrics, Trousseau Hospital, Paris, France
| |
Collapse
|
4
|
Loussert L, Vidal F, Parant O, Hamdi SM, Vayssiere C, Guerby P. Aspirin for prevention of preeclampsia and fetal growth restriction. Prenat Diagn 2020; 40:519-527. [PMID: 31955436 DOI: 10.1002/pd.5645] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 12/23/2019] [Accepted: 01/02/2020] [Indexed: 12/12/2022]
Abstract
For the past decades, growing attention has been given to aspirin use during pregnancy. It favors placentation by its proangiogenic, antithrombotic, and anti-inflammatory effects. Therefore, low doses of aspirin are prescribed in the prevention of placenta-mediated complications, mainly preeclampsia and fetal growth restriction. However, questions regarding its clinical application are still debated. Aspirin is effective in preventing preeclampsia in a high-risk population. Most guidelines recommend that risk stratification should rely on medical history. Nevertheless, screening performances dramatically improve if biochemical and biophysical markers are included. Concerning the appropriate timing and dose, latest studies suggest aspirin should be started before 16 weeks of pregnancy and at a daily dose of 100 mg or more. Further studies are needed to improve the identification of patients likely to benefit from prophylactic aspirin. Besides, the role of aspirin in the prevention of fetal growth restriction is still questioned.
Collapse
Affiliation(s)
- Lola Loussert
- Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France
| | - Fabien Vidal
- Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France
| | - Olivier Parant
- Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France
| | - Safouane M Hamdi
- Laboratoire de Biochimie et d'Hormonologie, Institut Fédératif de Biologie, CHU Toulouse, Toulouse, France
| | - Christophe Vayssiere
- Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France
| | - Paul Guerby
- Department of Obstetrics and Gynecology, Paule de Viguier Hospital, CHU Toulouse, Toulouse, France.,Inserm U-1048, Université de Toulouse, Toulouse, France
| |
Collapse
|
5
|
Hamdi SM, Sault C, Piver E, Genoux A, Masson D, Guibourdenche J. [Preeclampsia: Should screening and pronostic biomarkers be used in common clinical practice?]. Presse Med 2019; 48:1032-1036. [PMID: 31676218 DOI: 10.1016/j.lpm.2019.09.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 09/21/2019] [Indexed: 11/16/2022] Open
Affiliation(s)
- Safouane M Hamdi
- Groupe de recherche en fertilité humaine, EA3694, université Paul Sabatier, 31059 Toulouse, France; CHU de Toulouse, IFB, laboratoire de biochimie et d'hormonologie, 31059 Toulouse, France.
| | | | - Eric Piver
- CHRU de Tours, laboratoire de biochimie et biologie moléculaire, 37044 Tours, France
| | - Annelise Genoux
- CHU de Toulouse, IFB, laboratoire de biochimie et d'hormonologie, 31059 Toulouse, France
| | - Damien Masson
- CHRU de Nantes, laboratoire de Biochimie, 43095 Nantes, France
| | - Jean Guibourdenche
- AP-HP, hôpital Cochin, université Paris Descartes, laboratoire d'hormonologie, 75014 Paris, France
| |
Collapse
|
6
|
Duvillier C, Quibel T, Felsenheld C, Hupin-Genty L, Cohen C, Vialard F. [Cell-free DNA fraction: Can it be used to evaluate the risk of obstetrical issues?]. ACTA ACUST UNITED AC 2019; 47:790-796. [PMID: 31593819 DOI: 10.1016/j.gofs.2019.09.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Indexed: 01/17/2023]
Abstract
OBJECTIVE The aim of the study was to evaluate if fetal cell-free DNA (cfDNA) fraction circulating in maternal blood at the beginning of the second trimester is associated with obstetrical complications. METHODS This is a retrospective unicentric study conducted at the hospital of Poissy Saint Germain between the 1st January 2015, and the 31st. December 2016, Each woman who had a genetic counseling in order to realize a non-invasive prenatal test (NIPT) was included. Only singleton pregnancies with a documented-issue were analysed. The primary criteria was a composite criteria, defined as the occurrence of preeclampsia, in utero fetal growth, or a spontaneous preterm delivery. A descriptive analyse was first conducted, secondly completed by a sub-group one: "high fetal fraction" (>90th percentile) group, "low fetal-fraction" group (<10th percentile) and "medium fetal-fraction" (control group) group. RESULTS A total of 417 women had a cfDNA test, which was performed at a mean gestational age of 17.1 weeks of gestation. A total of 17% of pregnancies met the primary criteria. Among them, there were 8 (1.9%) pre-eclampsia, 49 (11.8%) intra-uterine growth restriction and 14 (3.4%) preterm births. There was no significant difference for the occurrence of the primary criteria (P>0.99) and of each obstetrical complication between each group. CONCLUSION Fetal cf-DNA fraction measured at the beginning of the second trimester is not associated with common obstetrical complications.
Collapse
Affiliation(s)
- C Duvillier
- Unité de recherche EA 7285, université de Versailles-Saint-Quentin en Yvelines, 2, avenue de la source de la Bièvre, 78180 Montigny-le-Bretonneux, France; Service d'obstétrique et gynécologie, centre hospitalier Poissy/Saint-germain, 10, rue du Champ-Gaillard, 78300 Poissy, France.
| | - T Quibel
- Réseau maternité en Yvelines et périnatalité active (MYPA), 20, rue Armagis, Pavillon Courtois, 78100 Saint-Germain-en-Laye, France; Service d'obstétrique et gynécologie, centre hospitalier Poissy/Saint-germain, 10, rue du Champ-Gaillard, 78300 Poissy, France
| | - C Felsenheld
- Service d'obstétrique et gynécologie, centre hospitalier Poissy/Saint-germain, 10, rue du Champ-Gaillard, 78300 Poissy, France
| | - L Hupin-Genty
- Service d'obstétrique et gynécologie, centre hospitalier Poissy/Saint-germain, 10, rue du Champ-Gaillard, 78300 Poissy, France
| | - C Cohen
- CHI Poissy/Saint-Germain-en-Laye, unités de génétique médicale et cytogénétique, 78300 Poissy, France
| | - F Vialard
- CHI Poissy/Saint-Germain-en-Laye, unités de génétique médicale et cytogénétique, 78300 Poissy, France; EA7404-GIG, université de Versailles-Saint-Quentin en Yvelines, 2, avenue de la source de la Bièvre, 78180 Montigny-le-Bretonneux, France
| |
Collapse
|
7
|
Guerby P, Sartor A, Vidal F, Vayssière C. Selective feticide as a treatment of severe preeclampsia in discordant twins. J Gynecol Obstet Hum Reprod 2019; 49:101633. [PMID: 31499281 DOI: 10.1016/j.jogoh.2019.101633] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Revised: 06/27/2019] [Accepted: 09/05/2019] [Indexed: 12/31/2022]
Abstract
Multifetal gestation is often complicated by the development of preeclampsia. In some twin gestations, preeclampsia develops in association with restricted fetal growth of only one fetus. Instead of termination of the entire pregnancy, we investigated an alternative approach to the management of such pregnancies that might allow unharmed survival of the normal twin. We present a case of preeclampsia in twin discordance with severe fetal growth restriction at 25 weeks of gestation. Preeclampsia was linked to a lethal condition in one twin and was treated with selective feticide in an effort to reverse preeclampsia. Inasmuch as the fetal prognosis was extremely poor for the abnormal fetus, selective feticide was a reasonable therapeutic option. Maternal symptoms resolved, allowing continuation of the pregnancy for 4 weeks before delivery of the healthy fetus. We maintain that selective termination induced a decrease in the release of substances involved in the physiopathology of preeclampsia, which allowed the continuation of the pregnancy with close follow-up. This report highlights the link between placental pathology and the disease process of preeclampsia and further supports selective termination as a reasonable management strategy in carefully selected cases of discordant twins.
Collapse
Affiliation(s)
- Paul Guerby
- Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; INSERM UMR 1048 I2MC, 31000, Toulouse, France.
| | - Agnès Sartor
- Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France
| | - Fabien Vidal
- Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; University of Toulouse III, 31000, Toulouse, France
| | - Christophe Vayssière
- Service de Gynécologie Obstétrique, 330 avenue de Grande Bretagne, Hopital Paule de Viguier, CHU Toulouse, 31059 Toulouse, France; University of Toulouse III, 31000, Toulouse, France
| |
Collapse
|
8
|
Pengjie Z, Xionghui C, Yueming Z, Ting X, Na L, Jianying T, Zhice X. LncRNA uc003fir promotes CCL5 expression and negatively affects proliferation and migration of trophoblast cells in preeclampsia. Pregnancy Hypertens 2018; 14:90-96. [DOI: 10.1016/j.preghy.2018.08.449] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 07/29/2018] [Accepted: 08/15/2018] [Indexed: 10/28/2022]
|
9
|
Genoux A, Guerby P, Morin M, Perret B, Vayssière C, Hamdi SM. [Targeted screening for pre-eclampsia in the first trimester of pregnancy at Toulouse University Hospital]. Ann Cardiol Angeiol (Paris) 2018; 67:111-118. [PMID: 29786509 DOI: 10.1016/j.ancard.2018.04.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 04/27/2018] [Indexed: 10/16/2022]
Abstract
GOALS Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality. Early treatment by aspirin has been shown to significantly reduce PE risk before 37weeks supporting the implementation of first-trimester screening. SUBJECTS AND METHODS A targeted screening was recently implemented at Toulouse University Hospital for women in their first pregnancy or those with personal or familial history of PE. It uses Fetal Medicine Foundation (FMF) algorithm that combines maternal characteristics, clinical, biophysical and biochemical (PAPP-A, Pregnancy Associated Plasma Protein-A, and PlGF, Placental Growth Factor) data. We describe this first population of pregnant women and compare our results with those of a mini-test that excludes PlGF and biophysical data. RESULTS Between October 2016 and September 2017, 500women have benefited from this screening. In such targeted population, we identified 3,6 % (n=18) of women at high risk to develop PE before 34weeks and 9,6 % (n=48) of women at high risk to develop PE between 34 and 37weeks. When we recalculated the risk using the mini-test, only 10women (56 %) were identified at high risk of early PE. CONCLUSION For the first time in France, we report the result of a targeted screening of PE during the first trimester using the FMF algorithm. We describe the screened population and show that it is more efficient than the mini-test.
Collapse
Affiliation(s)
- A Genoux
- Laboratoire de biochimie, institut fédératif de biologie, hôpital Purpan, CHU de Toulouse, 330, avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse cedex 9, France.
| | - P Guerby
- Service de gynécologie-obstétrique Paule-de-Viguier, hôpital Purpan, CHU de Toulouse 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France
| | - M Morin
- Service de gynécologie-obstétrique Paule-de-Viguier, hôpital Purpan, CHU de Toulouse 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France
| | - B Perret
- Laboratoire de biochimie, institut fédératif de biologie, hôpital Purpan, CHU de Toulouse, 330, avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse cedex 9, France
| | - C Vayssière
- Service de gynécologie-obstétrique Paule-de-Viguier, hôpital Purpan, CHU de Toulouse 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France
| | - S M Hamdi
- Laboratoire de biochimie, institut fédératif de biologie, hôpital Purpan, CHU de Toulouse, 330, avenue de Grande-Bretagne, TSA 40031, 31059 Toulouse cedex 9, France
| |
Collapse
|
10
|
|
11
|
Belhomme N, Doudnikoff C, Polard E, Henriot B, Isly H, Jego P. Aspirine : indications et utilisation durant la grossesse. Rev Med Interne 2017; 38:825-832. [DOI: 10.1016/j.revmed.2017.10.419] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 09/13/2017] [Accepted: 10/12/2017] [Indexed: 12/25/2022]
|